A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

Daniel Blockmans

Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium

Sara K. Penn

AbbVie, North Chicago, IL

Arathi R. Setty

AbbVie, North Chicago, IL

Wolfgang A. Schmidt

Department of Rheumatology, Waldfriede Hospital, Berlin

Andrea Rubbert-Roth

Division of Rheumatology and Immunology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Ellen M. Hauge

Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

Helen I. Keen

University of Western Australia Medical School, Fiona Stanley Hospital, Murdoch, Australia

Tomonori Ishii

Nader Khalidi

St. Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada

Christian Dejaco

Department of Rheumatology, Ospedale di Brunico, Azienda Sanitaria dell’Alto Adige, Brunico, Italy

Maria C. Cid

Department of Autoimmune Diseases, European Reference Network RITA, Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona

Bernhard Hellmich

Medius Kliniken, Teaching Hospital University of Tübingen, Department of Internal Medicine, Rheumatology, Pneumology, Nephrology and Diabetology, Kirchheim unter Teck, Germany

Meng Liu

Weihan Zhao

AbbVie, North Chicago, IL

Ivan Lagunes

AbbVie, North Chicago, IL

Ana B. Romero

AbbVie, North Chicago, IL

Peter K. Wung

AbbVie, North Chicago, IL

Peter A. Merkel

Division of Rheumatology, Department of Medicine, and the Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia